Search

Your search keyword '"Hoefsloot, Wouter"' showing total 277 results
Start Over Author "Hoefsloot, Wouter"
277 results on '"Hoefsloot, Wouter"'

4. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

Author

Aman, Jurjan, Duijvelaar, Erik, Botros, Liza, Kianzad, Azar, Schippers, Job R, Smeele, Patrick J, Azhang, Sara, Bartelink, Imke H, Bayoumy, Ahmed A, Bet, Pierre M, Boersma, Wim, Bonta, Peter I, Boomars, Karin A T, Bos, Lieuwe D J, van Bragt, Job J M H, Braunstahl, Gert-Jan, Celant, Lucas R, Eger, Katrien A B, Geelhoed, J J Miranda, van Glabbeek, Yurika L E, Grotjohan, Hans P, Hagens, Laura A, Happe, Chris M, Hazes, Boaz D, Heunks, Leo M A, van den Heuvel, Michel, Hoefsloot, Wouter, Hoek, Rianne J A, Hoekstra, Romke, Hofstee, Herman M A, Juffermans, Nicole P, Kemper, E Marleen, Kos, Renate, Kunst, Peter W A, Lammers, Ariana, van der Lee, Ivo, van der Lee, E Laurien, Maitland-van der Zee, Anke-Hilse, Mau Asam, Pearl F M, Mieras, Adinda, Muller, Mirte, Neefjes, Elisabeth C W, Nossent, Esther J, Oswald, Laurien M A, Overbeek, Maria J, Pamplona, Carolina C, Paternotte, Nienke, Pronk, Niels, de Raaf, Michiel A, van Raaij, Bas F M, Reijrink, Merlijn, Schultz, Marcus J, Serpa Neto, Ary, Slob, Elise M A, Smeenk, Frank W J M, Smit, Marry R, Smits, A Josien, Stalenhoef, Janneke E, Tuinman, Pieter R, Vanhove, Arthur L E M, Wessels, Jeroen N, van Wezenbeek, Jessie C C, Vonk Noordegraaf, Anton, de Man, Frances S, and Bogaard, Harm J

Published
2021
Full Text
View/download PDF

6. Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model

Author

Salillas, Sandra, primary, Raaijmakers, Jelmer, additional, Aarnoutse, Rob E., additional, Svensson, Elin M., additional, Asouit, Khalid, additional, van den Hombergh, Erik, additional, te Brake, Lindsey, additional, Stemkens, Ralf, additional, Wertheim, Heiman F. L., additional, Hoefsloot, Wouter, additional, and van Ingen, Jakko, additional

Published
2024
Full Text
View/download PDF

9. Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium aviumComplex Pulmonary Disease Treatment

Author

Zweijpfenning, Sanne M.H., Aarnoutse, Rob, Boeree, Martin J., Magis-Escurra, Cecile, Stemkens, Ralf, Geurts, Bram, van Ingen, Jakko, and Hoefsloot, Wouter

Abstract

Results of retrospective studies have suggested clofazimine as an alternative for rifampicin in the treatment of Mycobacterium aviumcomplex pulmonary disease (MAC-PD).

Published
2024
Full Text
View/download PDF

16. Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience

Author

Chiron, Raphael, primary, Hoefsloot, Wouter, additional, Van Ingen, Jakko, additional, Marchandin, Hélène, additional, Kremer, Laurent, additional, Morisse-Pradier, Hélène, additional, Charriot, Jeremy, additional, Mallet, Jean-Pierre, additional, Herrmann, Jean-Louis, additional, Caimmi, Davide, additional, Moreau, Johan, additional, Dumont, Yann, additional, Godreuil, Sylvain, additional, Bergeron, Anne, additional, Drevait, Margot, additional, Bouzat-Rossigneux, Elodie, additional, Terrail, Nicolas, additional, Andrejak, Claire, additional, Veziris, Nicolas, additional, Grenet, Dominique, additional, Coudrat, Alexandre, additional, and Catherinot, Emilie, additional

Published
2022
Full Text
View/download PDF

17. Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series

Author

van Arkel, Cynthia, primary, Boeree, Martin, additional, Magis-Escurra, Cécile, additional, Hoefsloot, Wouter, additional, Carpaij, Neeltje, additional, van Ingen, Jakko, additional, Pegge, Sjoert, additional, Wielders, Pascal, additional, Smeenk, Frank, additional, Aarnoutse, Rob, additional, Netea, Mihai G., additional, van Crevel, Reinout, additional, and van Laarhoven, Arjan, additional

Published
2022
Full Text
View/download PDF

19. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease:A NTM-NET study

Author

Henriette Zweijpfenning, Sanne Maria, Chiron, Raphael, Essink, Sharon, Schildkraut, Jodie, Akkerman, Onno W., Aliberti, Stefano, Altenburg, Josje, Arets, Bert, van Braeckel, Eva, Delaere, B. nédicte, Gohy, Sophie, Haarman, Eric, Lorent, Natalie, McKew, Genevieve, Morgan, Lucy, Wagner, Dirk, van Ingen, Jakko, Hoefsloot, Wouter, Microbes in Health and Disease (MHD), Pulmonary medicine, Pediatrics, Amsterdam Reproduction & Development (AR&D), UCL - (SLuc) Centre de référence pour la mucoviscidose, UCL - (SLuc) Service de pneumologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, Pulmonology, and AII - Infectious diseases

Subjects
lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Science & Technology, Critical Care Medicine, General & Internal Medicine, Respiratory System, Life Sciences & Biomedicine
Abstract

ispartof: CHEST vol:162 issue:1 pages:76-81 ispartof: location:United States status: published

Published
2022

21. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study

Author

Henriette Zweijpfenning, Sanne Maria, Chiron, Raphael, Essink, Sharon, Schildkraut, Jodie, Akkerman, Onno W., Aliberti, Stefano, Altenburg, Josje, Arets, Bert, van Braeckel, Eva, Delaere, Bénédicte, Gohy, Sophie, Haarman, Eric, Lorent, Natalie, McKew, Genevieve, Morgan, Lucy, Wagner, Dirk, van Ingen, Jakko, and Hoefsloot, Wouter

Published
2022
Full Text
View/download PDF

22. Safety and outcomes of amikacin liposome inhalation suspension for Mycobacterium abscessus pulmonary disease: a NTM-NET study.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Pathologie infectieuse, Sanne, Maria Henriette Zweijpfenning, Chiron, Raphael, Essink, Sharon, Schildkraut, Jodie, Akkerman, Onno W, Aliberti, Stefano, Altenburg, Josje, Arets, Bert, Van Braeckel, Eva, Delaere, Bénédicte, Gohy, Sophie, Haarman, Eric, Lorent, Natalie, McKew, Genevieve, Morgan, Lucy, Wagner, Dirk, van Ingen, Jakko, Hoefsloot, Wouter, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Pathologie infectieuse, Sanne, Maria Henriette Zweijpfenning, Chiron, Raphael, Essink, Sharon, Schildkraut, Jodie, Akkerman, Onno W, Aliberti, Stefano, Altenburg, Josje, Arets, Bert, Van Braeckel, Eva, Delaere, Bénédicte, Gohy, Sophie, Haarman, Eric, Lorent, Natalie, McKew, Genevieve, Morgan, Lucy, Wagner, Dirk, van Ingen, Jakko, and Hoefsloot, Wouter

Abstract

of conflict of interest: In, Ho have consulting fees to disclose. Ali has consulting fees, grants, participation on a DSMB and payment/honoraria. Ch has a grant to disclose. Br has grants, support for meetings and receipt of drugs to disclose. Wa has participation in clinical trials to disclose. Zw a grant and receipt of drugs to disclose. has Alt, Ar, Ak, De, Go, Ha, Lo, Mc, Mo, Sc, Es have nothing to disclose.

Published
2022

23. Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling

Author

Litjens, Carlijn H. C., Verscheijden, Laurens F. M., Bolwerk, Celine, Greupink, Rick, Koenderink, Jan B., van den Broek, Petra H. H., van den Heuvel, Jeroen J. M. W., Svensson, Elin, Boeree, Martin J., Magis-Escurra, Cecile, Hoefsloot, Wouter, van Crevel, Reinout, van Laarhoven, Arjan, van Ingen, Jakko, Kuipers, Saskia, Ruslami, Rovina, Burger, David M., Russel, Frans G. M., Aarnoutse, Rob E., Te Brake, Lindsey H. M., Litjens, Carlijn H. C., Verscheijden, Laurens F. M., Bolwerk, Celine, Greupink, Rick, Koenderink, Jan B., van den Broek, Petra H. H., van den Heuvel, Jeroen J. M. W., Svensson, Elin, Boeree, Martin J., Magis-Escurra, Cecile, Hoefsloot, Wouter, van Crevel, Reinout, van Laarhoven, Arjan, van Ingen, Jakko, Kuipers, Saskia, Ruslami, Rovina, Burger, David M., Russel, Frans G. M., Aarnoutse, Rob E., and Te Brake, Lindsey H. M.

Abstract

Moxifloxacin has an important role in the treatment of tuberculosis (TB). Unfortunately, coadministration with the cornerstone TB drug rifampicin results in suboptimal plasma exposure. We aimed to gain insight into the moxifloxacin pharmacokinetics and the interaction with rifampicin. Moreover, we provided a mechanistic framework to understand moxifloxacin pharmacokinetics. We developed a physiologically based pharmacokinetic model in Simcyp version 19, with available and newly generated in vitro and in vivo data, to estimate pharmacokinetic parameters of moxifloxacin alone and when administered with rifampicin. By combining these strategies, we illustrate that the role of P-glycoprotein in moxifloxacin transport is limited and implicate MRP2 as transporter of moxifloxacin-glucuronide followed by rapid hydrolysis in the gut. Simulations of multiple dose area under the plasma concentration-time curve (AUC) of moxifloxacin (400 mg once daily) with and without rifampicin (600 mg once daily) were in accordance with clinically observed data (predicted/observed [P/O] ratio of 0.87 and 0.80, respectively). Importantly, increasing the moxifloxacin dose to 600 mg restored the plasma exposure both in actual patients with TB as well as in our simulations. Furthermore, we extrapolated the single dose model to pediatric populations (P/O AUC ratios, 1.04-1.52) and the multiple dose model to children with TB (P/O AUC ratio, 1.51). In conclusion, our combined approach resulted in new insights into moxifloxacin pharmacokinetics and accurate simulations of moxifloxacin exposure with and without rifampicin. Finally, various knowledge gaps were identified, which may be considered as avenues for further physiologically based pharmacokinetic refinement.

Published
2022
Full Text
View/download PDF

24. Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease

Author

Danho, Rabi, Schildkraut, Jodie A., Zweijpfenning, Sanne M. H., Svensson, Elin, Pennings, Lian J., Kuipers, Saskia, Wertheim, Heiman F. L., Boeree, Martin J., Hoefsloot, Wouter, van Ingen, Jakko, Danho, Rabi, Schildkraut, Jodie A., Zweijpfenning, Sanne M. H., Svensson, Elin, Pennings, Lian J., Kuipers, Saskia, Wertheim, Heiman F. L., Boeree, Martin J., Hoefsloot, Wouter, and van Ingen, Jakko

Published
2022
Full Text
View/download PDF

25. Safety and outcomes of amikacin liposome inhalation suspension for Mycobacterium abscessus pulmonary disease: a NTM-NET study

Author

UCL - (SLuc) Centre de référence pour la mucoviscidose, UCL - (SLuc) Service de pneumologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, Zweijpfenning Sanne, Chiron, raphaël, Essink, Sharon, Schildkraut, Jodie, Akkerman, Onno, Aliberti, Stefano, Altenburg, Josje, Arets, Humbertus, Van Braeckel, Eva, Delaere, Bénédicte, Gohy, Sophie, Haarman, Eric, Lorent, Natalie, McKew, Genevieve, Morgan, Lucy, Wagner, Dirk, van Ingen, Jakko, Hoefsloot, Wouter, UCL - (SLuc) Centre de référence pour la mucoviscidose, UCL - (SLuc) Service de pneumologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, Zweijpfenning Sanne, Chiron, raphaël, Essink, Sharon, Schildkraut, Jodie, Akkerman, Onno, Aliberti, Stefano, Altenburg, Josje, Arets, Humbertus, Van Braeckel, Eva, Delaere, Bénédicte, Gohy, Sophie, Haarman, Eric, Lorent, Natalie, McKew, Genevieve, Morgan, Lucy, Wagner, Dirk, van Ingen, Jakko, and Hoefsloot, Wouter

Published
2022

26. RNA Sequencing Elucidates Drug-Specific Mechanisms of Antibiotic Tolerance and Resistance in Mycobacterium abscessus

Author

Schildkraut, Jodie A., primary, Coolen, Jordy P. M., additional, Burbaud, Sophie, additional, Sangen, Jasper J. N., additional, Kwint, Michael P., additional, Floto, R. Andres, additional, op den Camp, Huub J. M., additional, te Brake, Lindsey H. M., additional, Wertheim, Heiman F. L., additional, Neveling, Kornelia, additional, Hoefsloot, Wouter, additional, and van Ingen, Jakko, additional

Published
2022
Full Text
View/download PDF

27. Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling

Author

Litjens, Carlijn H. C., primary, Verscheijden, Laurens F. M., additional, Bolwerk, Celine, additional, Greupink, Rick, additional, Koenderink, Jan B., additional, van den Broek, Petra H. H., additional, van den Heuvel, Jeroen J. M. W., additional, Svensson, Elin M., additional, Boeree, Martin J., additional, Magis‐Escurra, Cecile, additional, Hoefsloot, Wouter, additional, van Crevel, Reinout, additional, van Laarhoven, Arjan, additional, van Ingen, Jakko, additional, Kuipers, Saskia, additional, Ruslami, Rovina, additional, Burger, David M., additional, Russel, Frans G. M., additional, Aarnoutse, Rob E., additional, and te Brake, Lindsey H. M., additional

Published
2021
Full Text
View/download PDF

29. Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19

Author

Aman, Jurjan, primary, Duijvelaar, Erik, additional, Botros, Liza, additional, Kianzad, Azar, additional, Schippers, Job, additional, Smeele, Patrick, additional, Azhang, Sara, additional, Bartelink, Imke, additional, Bet, Pierre, additional, Boersma, Wim, additional, Boomars, Karin, additional, Bonta, Peter, additional, Bos, Lieuwe, additional, Van Bragt, Job, additional, Braunstahl, Gert-Jan, additional, Celant, Lucas, additional, Eger, Katrien, additional, Geelhoed, Miranda, additional, Van Glabbeek, Yurika, additional, Grotjohan, Hans, additional, Hagens, Laura, additional, Happe, Chris, additional, Heunks, Leo, additional, Van Den Heuvel, Michel, additional, Hoefsloot, Wouter, additional, Hoek, Rianne, additional, Hoekstra, Romke, additional, Hofstee, Herman, additional, Vanhove, Arthur, additional, Juffermans, Nicole, additional, Lammers, Marije, additional, Kos, Renate, additional, Kemper, Marleen, additional, Kunst, Peter, additional, Van Der Lee, Ivo, additional, Van Der Lee, Laurien, additional, Mau-Asam, Pearl, additional, Maitland-Van Der Zee, Anke-Hilse, additional, Mieras, Adinda, additional, Nossent, Esther, additional, Overbeek, Marieke, additional, Oswald, Laurien, additional, Paternotte, Nienke, additional, Pamplona, Carol, additional, Pronk, Niels, additional, De Raaf, Michiel, additional, Slob, Elise, additional, Neto, Ary Serpa, additional, Schultz, Marcus, additional, Smit, Marry, additional, Smeenk, Frank, additional, Smits, Josien, additional, Stalenhoef, Janneke, additional, Tuinman, Pieter Roel, additional, Wessels, Jeroen, additional, Van Wezenbeek, Jessy, additional, Vonk Noordegraaf, Anton, additional, Handoko-De Man, Frances, additional, and Bogaard, Harm Jan, additional

Published
2021
Full Text
View/download PDF

30. Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease

Author

Griffith, David E., primary, Thomson, Rachel, additional, Flume, Patrick A., additional, Aksamit, Timothy R., additional, Field, Stephen K., additional, Addrizzo-Harris, Doreen J., additional, Morimoto, Kozo, additional, Hoefsloot, Wouter, additional, Mange, Kevin C., additional, Yuen, Dayton W., additional, Ciesielska, Monika, additional, Wallace, Richard J., additional, van Ingen, Jakko, additional, Brown-Elliott, Barbara A., additional, Coulter, Chris, additional, and Winthrop, Kevin L., additional

Published
2021
Full Text
View/download PDF

34. Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics

Author

Ruth, Mike Marvin, primary, Raaijmakers, Jelmer, additional, van den Hombergh, Erik, additional, Aarnoutse, Rob, additional, Svensson, Elin M., additional, Susanto, Budi O., additional, Simonsson, Ulrika S.H., additional, Wertheim, Heiman, additional, Hoefsloot, Wouter, additional, and van Ingen, Jakko, additional

Published
2021
Full Text
View/download PDF

36. Assessing COVID‐19 pneumonia—Clinical extension and risk with point‐of‐care ultrasound: A multicenter, prospective, observational study

Author

Lieveld, Arthur W. E., primary, Kok, Bram, additional, Azijli, Kaoutar, additional, Schuit, Frederik H., additional, Ven, Peter M., additional, Korte, Chris L., additional, Nijveldt, Robin, additional, den Heuvel, Frederik M. A., additional, Teunissen, Bernd P., additional, Hoefsloot, Wouter, additional, Nanayakkara, Prabath W. B., additional, and Bosch, Frank H., additional

Published
2021
Full Text
View/download PDF

37. An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies

Author

Sonawane, Vidhisha V., Ruth, Mike M., Pennings, Lian J., Svensson, Elin, Wertheim, Heiman F. L., Hoefsloot, Wouter, van Ingen, Jakko, Sonawane, Vidhisha V., Ruth, Mike M., Pennings, Lian J., Svensson, Elin, Wertheim, Heiman F. L., Hoefsloot, Wouter, and van Ingen, Jakko

Abstract

For Mycobacterium avium complex pulmonary disease (MAC-PD), current treatment regimens yield low cure rates. To obtain an evidence-based combination therapy, we assessed the in vitro activity of six drugs, namely, clarithromycin (CLR), rifampin (RIF), ethambutol (EMB), amikacin (AMK), clofazimine (CLO), and minocycline (MIN), alone and in combination, against Mycobacterium avium and studied the contributions of individual antibiotics to efficacy. The MICs of all antibiotics against M. avium ATCC 700898 were determined by broth microdilution. We performed kinetic time-kill assays of all single drugs and clinically relevant two-, three-, four-, and five-drug combinations against M. avium. Pharmacodynamic interactions of these combinations were assessed using area under the time-kill curve-derived effect size and Bliss independence. Adding a second drug yielded an average increase of the effect size (E) of 18.7% +/- 32.9%, although antagonism was seen in some combinations. Adding a third drug showed a smaller increase in effect size (112.2% +/- 11.5%). The RIF-CLO-CLR (E of 102 log(10) CFU/ml . day), RIF-AMK-CLR (E of 101 log(10) CFU/ml . day), and AMK-MIN-EMB (E of 97.8 log(10) CFU/ml . day) regimens proved more active than the recommended RIF-EMB-CLR regimen (E of 89.1 log(10) CFU/ml . day). The addition of a fourth drug had little impact on effect size (+14.54% +/- 3.08%). In vitro, several two- and three-drug regimens are as effective as the currently recommended regimen for MAC-PD. Adding a fourth drug to any regimen had little additional effect. In vitro, the most promising regimen would be RIF-AMK-macrolide or RIF-CLO-macrolide.

Published
2021
Full Text
View/download PDF

38. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

Author

Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, E., Madonsela, G., Magis Escurra, C., Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Šmite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D'Ambrosio, L., van den Boom, Martin, Sotgiu, Giovanni, Migliori, Giovanni Battista, Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, E., Madonsela, G., Magis Escurra, C., Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Šmite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D'Ambrosio, L., van den Boom, Martin, Sotgiu, Giovanni, and Migliori, Giovanni Battista

Published
2021

39. Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19

Author

CDL Staf Research, Circulatory Health, CDL Arcadia, Medische Staf Intensive Care, Infection & Immunity, Arts Assistenten Longziekten, Onderzoeksgroep 6, Janssen, Nico A.F., Grondman, Inge, de Nooijer, Aline H., Boahen, Collins K., Koeken, Valerie A.C.M., Matzaraki, Vasiliki, Kumar, Vinod, He, Xuehui, Kox, Matthijs, Koenen, Hans J.P.M., Smeets, Ruben L., Joosten, Irma, Brüggemann, Roger J.M., Kouijzer, Ilse J.E., van der Hoeven, Hans G., Schouten, Jeroen A., Frenzel, Tim, Reijers, Monique H.E., Hoefsloot, Wouter, Dofferhoff, Anton S.M., van Apeldoorn, Marjan J., Blaauw, Marc J.T., Veerman, Karin, Maas, Coen, Schoneveld, Arjan H., Hoefer, Imo E., Derde, Lennie P.G., van Deuren, Marcel, van der Meer, Jos W.M., van Crevel, Reinout, Giamarellos-Bourboulis, Evangelos J., Joosten, Leo A.B., van den Heuvel, Michel M., Hoogerwerf, Jacobien, de Mast, Quirijn, Pickkers, Peter, Netea, Mihai G., van de Veerdonk, Frank L., CDL Staf Research, Circulatory Health, CDL Arcadia, Medische Staf Intensive Care, Infection & Immunity, Arts Assistenten Longziekten, Onderzoeksgroep 6, Janssen, Nico A.F., Grondman, Inge, de Nooijer, Aline H., Boahen, Collins K., Koeken, Valerie A.C.M., Matzaraki, Vasiliki, Kumar, Vinod, He, Xuehui, Kox, Matthijs, Koenen, Hans J.P.M., Smeets, Ruben L., Joosten, Irma, Brüggemann, Roger J.M., Kouijzer, Ilse J.E., van der Hoeven, Hans G., Schouten, Jeroen A., Frenzel, Tim, Reijers, Monique H.E., Hoefsloot, Wouter, Dofferhoff, Anton S.M., van Apeldoorn, Marjan J., Blaauw, Marc J.T., Veerman, Karin, Maas, Coen, Schoneveld, Arjan H., Hoefer, Imo E., Derde, Lennie P.G., van Deuren, Marcel, van der Meer, Jos W.M., van Crevel, Reinout, Giamarellos-Bourboulis, Evangelos J., Joosten, Leo A.B., van den Heuvel, Michel M., Hoogerwerf, Jacobien, de Mast, Quirijn, Pickkers, Peter, Netea, Mihai G., and van de Veerdonk, Frank L.

Published
2021

40. Risk factors for in-hospital mortality in laboratory-confirmed COVID-19 patients in the Netherlands: A competing risk survival analysis

Author

Nijman, Gerine, primary, Wientjes, Maike, additional, Ramjith, Jordache, additional, Janssen, Nico, additional, Hoogerwerf, Jacobien, additional, Abbink, Evertine, additional, Blaauw, Marc, additional, Dofferhoff, Ton, additional, van Apeldoorn, Marjan, additional, Veerman, Karin, additional, de Mast, Quirijn, additional, ten Oever, Jaap, additional, Hoefsloot, Wouter, additional, Reijers, Monique H., additional, van Crevel, Reinout, additional, and van de Maat, Josephine S., additional

Published
2021
Full Text
View/download PDF

41. Clinical characteristics and outcomes of 952 hospitalized COVID-19 patients in The Netherlands: A retrospective cohort study

Author

Pouw, Niels, primary, van de Maat, Josephine, additional, Veerman, Karin, additional, ten Oever, Jaap, additional, Janssen, Nico, additional, Abbink, Evertine, additional, Reijers, Monique, additional, de Mast, Quirijn, additional, Hoefsloot, Wouter, additional, van Crevel, Reinout, additional, Slieker, Kitty, additional, van Apeldoorn, Marjan, additional, Blaauw, Marc, additional, Dofferhoff, Anton, additional, and Hoogerwerf, Jacobien, additional

Published
2021
Full Text
View/download PDF

42. A limited role of cytokine storm and fibrogenesis in COVID-19 related liver injury

Author

Westerouen van Meeteren, Menso J, primary, Van den Heuvel, Frederik M.A., primary, Weijers, Gert, primary, Joosten, Leo A.B., primary, De Mast, Quirijn, primary, Van de Veerdonk, Frank L., primary, Pickkers, Peter, primary, De Nooijer, Aline H., primary, Hoefsloot, Wouter, primary, Drenth, Joost P.H., primary, De Korte, Chris L., primary, Nijveldt, Robin, primary, Netea, Mihai G., primary, and Tjwa, Eric T.T.L., primary

Published
2021
Full Text
View/download PDF

43. Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19

Author

Janssen, Nico A F, primary, Grondman, Inge, additional, de Nooijer, Aline H, additional, Boahen, Collins K, additional, Koeken, Valerie A C M, additional, Matzaraki, Vasiliki, additional, Kumar, Vinod, additional, He, Xuehui, additional, Kox, Matthijs, additional, Koenen, Hans J P M, additional, Smeets, Ruben L, additional, Joosten, Irma, additional, Brüggemann, Roger J M, additional, Kouijzer, Ilse J E, additional, van der Hoeven, Hans G, additional, Schouten, Jeroen A, additional, Frenzel, Tim, additional, Reijers, Monique H E, additional, Hoefsloot, Wouter, additional, Dofferhoff, Anton S M, additional, van Apeldoorn, Marjan J, additional, Blaauw, Marc J T, additional, Veerman, Karin, additional, Maas, Coen, additional, Schoneveld, Arjan H, additional, Hoefer, Imo E, additional, Derde, Lennie P G, additional, van Deuren, Marcel, additional, van der Meer, Jos W M, additional, van Crevel, Reinout, additional, Giamarellos-Bourboulis, Evangelos J, additional, Joosten, Leo A B, additional, van den Heuvel, Michel M, additional, Hoogerwerf, Jacobien, additional, de Mast, Quirijn, additional, Pickkers, Peter, additional, Netea, Mihai G, additional, and van de Veerdonk, Frank L, additional

Published
2021
Full Text
View/download PDF

44. Mycobacterium xenopi clinical relevance and determinants, the Netherlands

Author

van Ingen, Jakko, Boeree, Martin J., de Lange, Wiel C.M., Hoefsloot, Wouter, Bendien, Saar A., Magis-Escurra, Cecile, Dekhuijzen, Richard, and van Soolingen, Dick

Subjects
Mycobacteria -- Health aspects, Mycobacteria -- Control, Mycobacterium -- Health aspects, Mycobacterium -- Control, Mycobacterial infections -- Diagnosis, Mycobacterial infections -- Care and treatment, Mycobacterial infections -- Demographic aspects
Abstract

In the Netherlands, isolation of Mycobacterium xenopi is infrequent, and its clinical relevance is often uncertain. To determine clinical relevance and determinants, we retrospectively reviewed medical files of all patients [...]

Published
2008

45. Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?

Author

Ruth, Mike Marvin, Koeken, Valerie A. C. M., Pennings, Lian J., Svensson, Elin, Wertheim, Heiman F. L., Hoefsloot, Wouter, van Ingen, Jakko, Ruth, Mike Marvin, Koeken, Valerie A. C. M., Pennings, Lian J., Svensson, Elin, Wertheim, Heiman F. L., Hoefsloot, Wouter, and van Ingen, Jakko

Abstract

Background: Pulmonary infections caused by non-tuberculous mycobacteria (NTM) are hard to treat and have low cure rates despite intensive multidrug therapy. Objectives: To assess the feasibility of tedizolid, a new oxazolidinone, for the treatment of Mycobacterium avium and Mycobacterium abscessus. Methods: We determined MICs of tedizolid for 113 isolates of NTM. Synergy with key antimycobacterial drugs was assessed using the chequerboard method and calculation of the FIC index (FICI). We performed time-kill kinetics assays of tedizolid alone and combined with amikacin for M. abscessus and with ethambutol for M. avium. Human macrophages were infected with M. abscessus and M. avium and subsequently treated with tedizolid; intracellular and extracellular cfu were quantified over time. Results: NTM isolates generally had a lower MIC of tedizolid than of linezolid. FICIs were lowest between tedizolid and amikacin for M. abscessus (FICI = 0.75) and between tedizolid and ethambutol for M. avium (FICI = 0.72). Clarithromycin and tedizolid showed initial synergy, which was abrogated by erm(41)-induced macrolide resistance (FICI = 0.53). Tedizolid had a weak bacteriostatic effect on M. abscessus and combination with amikacin slightly prolonged its effect. Tedizolid had concentration-dependent activity against M. avium and its efficacy was enhanced by ethambutol. Both combinations had a concentration-dependent synergistic effect. Tedizolid could inhibit the intracellular bacterial population of both M. avium and M. abscessus. Conclusions: Tedizolid should be further investigated in pharmacodynamic studies and clinical trials for M. avium complex pulmonary disease. It is less active against M. abscessus, but still promising.

Published
2020
Full Text
View/download PDF

48. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study

Author

Akkerman, Onno, Aleksa, Alena, Alffenaar, Jan-Willem, Al-Marzouqi, Nada Hassan, Arias-Guillén, Miguel, Belilovski, Evgeny, Bernal, Enrique, Boeree, Martin J., Borisov, Sergey E., Bruchfeld, Judith, Cadiñanos Loidi, Julen, Cai, Qingshan, Caminero, Jose A., Cebrian Gallardo, Jose Joaquín, Centis, Rosella, Codecasa, Luigi Ruffo, D’Ambrosio, Lia, Dalcolmo, Margareth, Danila, Edvardas, Dara, Masoud, Davidavičienė, Edita, Davies Forsman, Lina, De Los Rios Jefe, Jorge, Denholm, Justin, Duarte, Raquel, Elamin, Seifeldin Eltaeb, Ferrarese, Maurizio, Filippov, Alexey, Ganatra, Shashank, Garcia, Ana, García-García, José-María, Gayoso, Regina, Giraldo Montoya, Angela Maria, Gomez Rosso, Roscio Gomez, Gualano, Gina, Hoefsloot, Wouter, Ilievska-Poposka, Biljana, Jonsson, Jerker, Khimova, Elena, Kuksa, Liga, Kunst, Heinke, Laniado-Laborín, Rafael, Li, Yang, Magis-Escurra, Cecile, Manfrin, Vinicio, Manga, Selene, Marchese, Valentina, Martínez Robles, Elena, Maryandyshev, Andrei, Matteelli, Alberto, Migliori, Giovanni Battista, Mullerpattan, Jai B., Munoz-Torrico, Marcela, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Noordin, Noorliza Mohamad, Palmero, Domingo Juan, Palmieri, Fabrizio, Payen, Marie-Christine, Piubello, Alberto, Pontali, Emanuele, Pontarelli, Agostina, Quirós, Sarai, Rendon, Adrian, Skrahina, Alena, Šmite, Agnese, Solovic, Ivan, Sotgiu, Giovanni, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Stošić, Maja, Tadolini, Marina, Tiberi, Simon, Udwadia, Zarir Farokh, van den Boom, Martin, Vescovo, Marisa, Viggiani, Pietro, Visca, Dina, Zhurkin, Dmitry, and Zignol, Matteo

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results